​

Funding Round

Series C - Moximed

Series C - Moximed

Investment Firm

Overview

Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.

Announced Date

Mar 17, 2017

Closed on Date

Mar 17, 2017

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Advent Life Sciences

Advent Life Sciences

Advent Life Sciences is a early_stage_venture and late_stage_venture and seed and venture firm.

Future Fund

Future Fund

No designation

Participant Investors

7

Investor Name
Participant InvestorGBS Ventures
Participant InvestorAdvent Life Sciences
Participant InvestorMorgenthaler Ventures
Participant InvestorVertex Ventures
Participant InvestorNew Enterprise Associates

Round Details and Background

Moximed raised $50000000 on 2017-03-17 in Series C

Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.

Company Funding History

8

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 27, 2016
Series B - Moximed
3-12.6M
May 07, 2015
Series B - Moximed
6-33.0M
Jan 01, 2012
Venture Round - Moximed
4-1.8M
Dec 05, 2011
Series A - Moximed
-45.8M

Recent Activity

There is no recent news or activity for this profile.